MedTrace Logo

Study of FCN-437c in Patients With Advanced Solid Tumors

NCT03951116 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2022-03-16

No results posted yet for this study

Summary

This research study is studying a drug called FCN-437c as a possible treatment for patients with advanced unresectable/metastatic solid tumors.

Conditions

  • Solid Tumor, Adult

Interventions

DRUG

FCN-437

FCN-437c is a selective and potent CDK4/6 dual inhibitor, with broad antitumor activity in preclinical pharmacology models, favorable physical and pharmacokinetic (PK) properties, and acceptable toxicity profile in nonclinical studies.

Sponsors & Collaborators

  • Fochon Pharmaceuticals, Ltd.

    lead INDUSTRY

Principal Investigators

  • Amita Patmaik, MD · South Texas Accelerated Research Therapeutics

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-25
Primary Completion
2021-12-08
Completion
2021-12-08
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03951116 on ClinicalTrials.gov